{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:04Z","timestamp":1790743864227,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.cyto.2018.12.018","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T12:45:45Z","timestamp":1548420345000},"page":"154635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Type I interferon dysregulation in Systemic Sclerosis"],"prefix":"10.1016","volume":"132","author":[{"given":"Brian","family":"Skaug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.cyto.2018.12.018_b0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2018.12.018_b0010","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"10.1016\/j.cyto.2018.12.018_b0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.cyto.2018.12.018_b0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.bor.0000434672.77891.41","article-title":"What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?","volume":"25","author":"Assassi","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cyto.2018.12.018_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2017.05.004","article-title":"Unfolding the pathogenesis of scleroderma through genomics and epigenomics","volume":"83","author":"Tsou","year":"2017","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2018.12.018_b0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-med-052814-023338","article-title":"Importance of nucleic acid recognition in inflammation and autoimmunity","volume":"67","author":"Barrat","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cyto.2018.12.018_b0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.26.021607.090400","article-title":"The IRF family transcription factors in immunity and oncogenesis","volume":"26","author":"Tamura","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2018.12.018_b0050","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S","article-title":"Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts","volume":"44","author":"Arnett","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.cyto.2018.12.018_b0055","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","article-title":"Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies","volume":"48","author":"Feghali-Bostwick","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/art.24183","article-title":"Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis","volume":"60","author":"Dieude","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.cyto.2018.12.018_b0065","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/art.24600","article-title":"Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population","volume":"60","author":"Ito","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0070","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3899\/jrheum.091163","article-title":"Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity","volume":"37","author":"Dieude","year":"2010","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.565","article-title":"Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus","volume":"42","author":"Radstake","year":"2010","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajhg.2013.12.002","article-title":"Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis","volume":"94","author":"Mayes","year":"2014","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0085","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s13075-014-0438-8","article-title":"An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3","volume":"16","author":"Zochling","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.cyto.2018.12.018_b0090","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/annrheumdis-2011-200901","article-title":"IRF5 polymorphism predicts prognosis in patients with systemic sclerosis","volume":"71","author":"Sharif","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"49","key":"10.1016\/j.cyto.2018.12.018_b0095","doi-asserted-by":"crossref","first-page":"15136","DOI":"10.1073\/pnas.1520997112","article-title":"Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis","volume":"112","author":"Saigusa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.cyto.2018.12.018_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002178","article-title":"Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy","volume":"7","author":"Gorlova","year":"2011","journal-title":"PLoS Genet"},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/art.37777","article-title":"PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population","volume":"65","author":"Terao","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2018.12.018_b0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-015-0572-y","article-title":"Identification of NF-kappaB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis","volume":"17","author":"Arismendi","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/annrheumdis-2011-200275","article-title":"Novel iden tification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis","volume":"71","author":"Carmona","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2018.12.018_b0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/art.30193","article-title":"Association of a functional IRF7 variant with systemic lupus erythematosus","volume":"63","author":"Fu","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.cyto.2018.12.018_b0125","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.39730","article-title":"Brief report: IRF4 newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies","volume":"68","author":"Lopez-Isac","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"5589","key":"10.1016\/j.cyto.2018.12.018_b0130","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0135","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/hmg\/ddp119","article-title":"The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype","volume":"18","author":"Rueda","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.cyto.2018.12.018_b0140","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/art.24688","article-title":"STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis","volume":"60","author":"Dieude","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cyto.2018.12.018_b0145","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/ard.2009.111310","article-title":"Association of STAT4 polymorphism with systemic sclerosis in a Japanese population","volume":"68","author":"Tsuchiya","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/039463201302600220","article-title":"STAT4 is a genetic risk factor for systemic sclerosis in a Chinese population","volume":"26","author":"Yi","year":"2013","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"7","key":"10.1016\/j.cyto.2018.12.018_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002091","article-title":"Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis","volume":"7","author":"Allanore","year":"2011","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.cyto.2018.12.018_b0160","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1002\/art.24958","article-title":"Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1\/Th2 cytokines","volume":"60","author":"Gourh","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cyto.2018.12.018_b0170","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.cyto.2018.12.018_b0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.cyto.2018.12.018_b0180","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0185","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.23451","article-title":"Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma","volume":"58","author":"Duan","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0195","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1756-185X.2011.01654.x","article-title":"Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients","volume":"15","author":"Higgs","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.cyto.2018.12.018_b0205","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T cell activation and collagen accumulation by an Anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.cyto.2018.12.018_b0210","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cyto.2018.12.018_b0220","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/art.40243","article-title":"Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum","volume":"69","author":"Cossu","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0225","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004005","article-title":"Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms","volume":"11","author":"Mahoney","year":"2015","journal-title":"PLoS Comput. Biol."},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0235","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.cyto.2018.12.018_b0240","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2018.12.018_b0245","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1465-9921-14-80","article-title":"Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease","volume":"14","author":"Lindahl","year":"2013","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.cyto.2018.12.018_b0250","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.4049\/jimmunol.1300376","article-title":"A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling","volume":"191","author":"Fang","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1165\/rcmb.2003-0374OC","article-title":"Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin","volume":"32","author":"Azuma","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0260","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.2002.48901.x","article-title":"Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders","volume":"147","author":"Beretta","year":"2002","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0265","first-page":"625","article-title":"Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis","volume":"22","author":"Solans","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2018.12.018_b0270","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2169\/internalmedicine.46.6328","article-title":"Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C","volume":"46","author":"Tahara","year":"2007","journal-title":"Intern. Med."},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0275","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s10067-008-0972-3","article-title":"The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment","volume":"27","author":"Powell","year":"2008","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"7030","key":"10.1016\/j.cyto.2018.12.018_b0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature03308","article-title":"Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors","volume":"434","author":"Takaoka","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cyto.2018.12.018_b0290","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.30171","article-title":"Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cyto.2018.12.018_b0295","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1385\/IR:31:3:231","article-title":"STAT4: a critical regulator of inflammation in vivo","volume":"31","author":"Kaplan","year":"2005","journal-title":"Immunol. Res."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0300","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.immuni.2007.06.009","article-title":"The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8","volume":"27","author":"Tailor","year":"2007","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.cyto.2018.12.018_b0305","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1101\/gad.1104803","article-title":"IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development","volume":"17","author":"Lu","year":"2003","journal-title":"Genes Dev."},{"issue":"12","key":"10.1016\/j.cyto.2018.12.018_b0310","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2012.08.011","article-title":"Targeting IRF4 in autoimmune diseases","volume":"11","author":"Xu","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2018.12.018_b0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The Type I Interferonopathies","volume":"68","author":"Lee-Kirsch","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"7","key":"10.1016\/j.cyto.2018.12.018_b0320","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.cyto.2018.12.018_b0325","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0330","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1038\/jid.2010.200","article-title":"Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis","volume":"130","author":"Farina","year":"2010","journal-title":"J. Invest Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2018.12.018_b0335","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/ard.2010.132464","article-title":"dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts","volume":"70","author":"Farina","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0340","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar3221","article-title":"Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts","volume":"13","author":"Agarwal","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2006.12.002","article-title":"Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors","volume":"19","author":"Miyake","year":"2007","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0350","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"232","key":"10.1016\/j.cyto.2018.12.018_b0355","doi-asserted-by":"crossref","first-page":"p. 232ra50","DOI":"10.1126\/scitranslmed.3008264","article-title":"FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling","volume":"6","author":"Bhattacharyya","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0360","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38901","article-title":"Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis","volume":"67","author":"Takahashi","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"21","key":"10.1016\/j.cyto.2018.12.018_b0365","doi-asserted-by":"crossref","first-page":"15319","DOI":"10.1074\/jbc.R700009200","article-title":"Toll-like receptors and Type I interferons","volume":"282","author":"Uematsu","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cyto.2018.12.018_b0370","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/jid.2013.423","article-title":"Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma","volume":"134","author":"Farina","year":"2014","journal-title":"J. Invest Dermatol."},{"issue":"423","key":"10.1016\/j.cyto.2018.12.018_b0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.cyto.2018.12.018_b0380","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0385","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/art.39733","article-title":"Prion-like aggregation of mitochondrial antiviral signaling protein in lupus patients is associated with increased levels of type I interferon","volume":"68","author":"Shao","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.12.018_b0390","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.40002","article-title":"Expression of cyclic GMP-AMP synthase in patients with systemic lupus erythematosus","volume":"69","author":"An","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0395","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2016.09.008","article-title":"Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop","volume":"137","author":"Stannard","year":"2017","journal-title":"J. Invest Dermatol."},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0400","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/rheumatology\/kex280","article-title":"Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta","volume":"56","author":"McCoy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.cyto.2018.12.018_b0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0410","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","article-title":"Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease","volume":"18","author":"Volkmann","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0415","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.cyto.2018.12.018_b0420","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cyto.2018.12.018_b0425","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.12.018_b0430","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619300067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619300067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:56:17Z","timestamp":1760907377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466619300067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":86,"alternative-id":["S1043466619300067"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2018.12.018","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I interferon dysregulation in Systemic Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2018.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154635"}}